Prostate Cancer News
Biomarkers of PD-1/PD-L1 checkpoint inhibitor response in prostate cancer could help stratify patients by response.
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
In a Spanish study, the highest vs lowest tertile of dietary zinc intake was associated with a significant 66% increased relative risk of low-grade prostate cancer.
Statin use by men receiving androgen deprivation therapy for advanced PCa was associated with decreased risk of overall and cancer-specific mortality.
A study suggests HIMRT may have some advantages over CIMRT for treating men with localized prostate cancer.
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
Radiotherapy may improve survival among men with low metastatic burden, but not in all patients with metastatic prostate cancer.
The regimen did not improve survival and increased bone fractures.
Cancer occurrence in island Puerto Ricans and Puerto Ricans living in the continental US and Hawaii differ considerably.
In a recently published study, external beam radiation therapy for localized prostate cancer was associated with a 35% increased risk of bladder cancer compared with radical prostatectomy.
Men treated with radical prostatectomy plus radiotherapy for locally or regionally advanced prostate cancer had improved survival but worse adverse events.
Differences in TMB between African and European patients show that "racial mutational disparity is not a technical or computational artifact," according to authors.
Epigenetic changes in the tumor microenvironment may explain why prostate cancer patients develop resistance to androgen signaling deprivation therapy.
Some prostate cancer cells lack androgen receptors, and they proliferate faster than those that express androgen receptors under androgen-deficient conditions.
Recent analyses suggest that lifetime intake and early-life alcohol use may significantly contribute to the development of high-grade prostate cancer.
Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.
The effect of age on outcomes in active surveillance is not well reported and requires further study.
First-Line Enzalutamide May Confer a Survival Benefit for Metastatic Castration-Resistant Prostate Cancer
Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Some prior evidence has linked increased sugar consumption to cancer development, but its impact on prostate cancer is unknown.
This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- Fermented Dairy and Cancer
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC